Salivary-Free Catecholamines Metabolites in Pheochromocytoma Abstract #510

Introduction: Salivary monitoring of hormone levels have many advantages over the more conventional serum/plasma analysis. Salivary-free metanephrines (MN) and normetanephrines (NMN) could improve biochemical diagnosis of pheochromocytoma (PHEO) as an alternative to plasma metabolites.
Aim(s): To evaluate the value of salivary catecholamine metabolites in patients with suspected pheochromocytoma, as compared with plasma catecholamine metabolites values.
Materials and methods: The prospective case-control study included a group of 30 patients confirmed with PHEO, an age-matched control group of 70 normotensive subjects. The PHEO diagnosis was suspected on clinical grounds and confirmed by imaging studies and classical neuroendocrine markers. Free plasma and salivary NMN and MN were assayed using enzyme immunoassay for both metabolites.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Corin Badiu

To read results and conclusion, please login ...

Further abstracts you may be interested in

#142 The role of 18F DOPA-PET in a case of malignant pheochromcytoma
Introduction: Pheocromocytoma is a rare tumor arising from chromaffin cells of adrenal medullary or extra adrenal paraganglionic tissue. Histological criteria cannot differentiate benign from malignant pheocromocytomas. The diagnosis of a malignant pheocromocytoma requires local invasion, recurrence and documented metastatic disease. The radionuclide scanning (123I - 131I-MIBG) is a fundamental diagnostic tool used to confirm the biochemical and radiological diagnosis of pheochromocytoma. In fact, MIBG scanning may confirm that the visualised lesion in an adrenal gland is indeed a pheochromocytoma and detect extra-adrenal paraganglionic tissue. However, MIBG scans are negative in around 15% of benign pheochromocytomas and in up to 50% of malignant ones. Other radionuclide techniques (18FDG-PET, 18F-DOPA-PET, 18F-FDA-PET) have been successfully used in investigation of pheochromocytomas. 18F-DOPA-PET and 18F-FDA-PET have been reported to be highly sensitive and specific for benign pheochromocytomas, while 18FDG-PET can be useful for malignant lesions with higher metabolic activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Laura De Marinis
#527 Pheochromocytoma Molecular Analysis After Maternal Transmission of SDHD Mutation Elucidates Mechanism of Parent-of-Origin Effect
Introduction: In SDHD mutation families, paragangliomas and pheochromocytomas usually occur only after paternal transmission of the mutation. This important but unexplained parent-of-origin effect is not due to imprinting of the SDHD gene itself (as was initially suspected) since SDHD is biallelically expressed.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Edward Tobias
Authors: Tobias E, Yeap P, Mavraki E, Fletcher A, ...
#269 Expression of IGF/mTOR Pathway Components in Human Pheochromocytomas and In Vitro Inhibition of PC12 Rat Pheochromocytoma Cell Growth by mTOR Inhibitors
Introduction: The pathogenesis of pheochromocytomas (pheo) is poorly understood and malignant pheo need new treatment options. mTOR inhibitors, as sirolimus(S) and everolimus(E), are promising antineoplastic drugs.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MD Maria Cristina De Martino
#850 Expression of IGF/mTOR Pathway Components in Human Pheochromocytomas and In Vitro Inhibition of PC12 rat Pheochromocytoma Cell Growth by mTOR Inhibitors alone and in Combination with the Dual IGFI-R/INS-R Antagonist OSI-906
Introduction: Dysregulation of the mTOR and IGF pathways have been suggested to be involved in the pathogenesis of pheochromocytomas (PCC). mTOR inhibitors, such as sirolimus (S) and everolimus (E), as well as IGFI-R antagonists such as OSI-906, could be new a treatment for malignant PPC.
Conference: 11th Annual ENETS Conference (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Maria Cristina De Martino
#1027 Chromogranin A (CgA) in Pheochromocytoma and in Multiple Endocrine Neoplasia Type 1.
Introduction: Chromogranin A (CgA) as a main, nonspecific marker of neuroendocrine tumors (NET) has been applied for diagnostic purposes and for monitoring the treatment of NET. Pheochromocytoma and MEN-1 syndrome represent rare neuroendocrine tumours.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: M.Sc., Ph.D. Piotr Glinicki